Primary brain and central nervous system (CNS) tumours (ICD-10 codes C70-C72) are a group of primary tumours arising in the brain, meninges or central nervous system. As such, this is a cluster of conditions rather than one disease per se. There are considered to be over 120 types of brain tumour including glioblastoma multiforme (GBM), meningiomas and astrocytomas.
This report provides the current incident population for Brain & CNS Cancer across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Turkey, Russia, India, Canada, Australia, Japan, China, South Korea, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Brain & CNS Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Brain & CNS Cancer include:
• Genetic susceptibility
• Family history of brain & CNS cancers
• Ionizing radiation exposure
• Non-ionizing radiation exposure (e.g. mobile phones, electromagnetic fields)
• Growth hormone deficiencies
• Epilepsy & seizures
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Brain & CNS Cancer’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Brain & CNS Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Brain and CNS Cancer’s incident population.
• Identify sub-populations within Brain & CNS Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Brain & CNS Cancer patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Brain & CNS Cancer Incidence
• Location and Histopathology of Brain & CNS Cancer
o Location of Brain & CNS Cancer
o Histopathology of Neuroepithelial Brain & CNS Cancer
o Glioblastoma Multiforme and Other Types of Glial Brain & CNS Cancer
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Risk factors for gliomas and meningiomas
• WHO Histologic grading for CNS tumours
• Karnofsky Performance Scale (KPS) for functional assessment
• Incidence of Brain & CNS Cancer, total (000s)
• Incidence of Brain & CNS Cancer, males (000s)
• Incidence of Brain & CNS Cancer, females (000s)
• Location of Brain & CNS Cancer tumour, total (000s)
• Incidence of Neuroepithelial Brain & CNS Cancer, total (000s)
• Histopathology of neuroepithelial Brain & CNS Cancers, total (000s)
• Incidence of Glioblastoma Multiforme and other glial cell histopathologies, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• USA Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• France Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• France Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Germany Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Germany Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Italy Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Italy Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Spain Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Spain Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• United Kingdom Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• United Kingdom Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Turkey Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Turkey Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Russia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Russia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• India Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• India Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Canada Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Canada Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Australia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Australia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Japan Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Japan Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• China Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• China Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• South Korea Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• South Korea Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Argentina Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Argentina Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Brazil Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Brazil Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Mexico Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Mexico Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• South Africa Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• South Africa Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
List of Figures
• Tumour location – contribution by gender
• Total Incident Brain & CNS tumours by location, males vs females
